Chemo Group founder Hugo Sigman visits Shanghai

Mr. Hugo Sigman, the founder of Chemo Group, took part in the G20 Global Agricultural Entrepreneur Summit held in Xi'an and made a special trip to our Shanghai office to visit and cordially greet the staff and guide our business development work.

Mr. Sigman has friendly interaction with our staff

First of all, Mr. Sigman gave a general introduction to the Group's business in China, for example: cooperation with Fosun Group - Maowanbang Biomedicine; China-Africa Agricultural Demonstration Project, Foot and Mouth Disease Vaccine Investment Production Base - Xi'an Yangling Jinhai Biotechnology Co., Ltd. This is the key discussion project of the G20 Agriculture Ministers Meeting; and the cooperation with Sinopharm Group on anticancer drugs. At the same time, we also shared with us the relevant business development in Argentina. The Group has a wide range of industries in Argentina, including: pharmaceutical industry, agriculture, animal husbandry, news publishing, film industry and so on. The core business of the world is the pharmaceutical industry, covering the entire industrial chain operation from the import of raw materials, research and development, production to the export of branded drugs.

Talking about some of his investment experiences in China. Mr. Sigman said that China is one of the most important markets in the world. Chemo Group will strengthen cooperation with Chinese local companies in research, technology and production, and steadily increase investment in China to achieve the Group's strategic goals in China.

In response to the urgent needs of our staff, Mr. Sigman also answered one by one:

1. We all know that Chemo is a well-known global group. As a branch of the group in Shanghai, how is the headquarters positioned for Exeltis China?

Mr. Sigman: As a strategic fulcrum in China, Exeltis China not only carries the heavy responsibility of our brand drug registration and import, but also the window of China's API export and Chemo Group's R&D test sites in China. In the next few years, Exeltis China will have more innovative drug registrations, including our gynecological drugs, and we will expand the sales team to further develop our strategic layout in China.

2. Under the trend of stricter drug price reduction and tendering in China, what do you think about the opportunities and challenges we face in China?

Mr. Sigman: The current changes in the pharmaceutical market in China have occurred on a global scale. For example, in Germany, there are similar phenomena. This trend can help us reduce our competitors, clear up some obstacles, and let us find our own shortcomings. Of course, the increase in cost and the price drop will continue to drive down our profit margins, but I believe that under the leadership of Sun, Exeltis China can overcome the immediate difficulties and guarantee our profits to the greatest extent.

3. We know that you are a very successful entrepreneur in Argentina, the “business legend” of Latin America, then what is your childhood dream?

Mr. Sigman: My mother's family is a relatively large family. I am also the grandson of grandparents. They have high expectations for me. When I was a doctor, I found that the attitude of the doctor to the patient was not ideal. It was more to treat the patient as an "object" or a "broken machine". I want to change this situation. This is my original intention in the pharmaceutical industry. I hope that through our efforts, more people will get better treatment in time.

Friendly and patient answer to questions raised by employees (front row, left: Mr. Lin, Mr. Sigman, Mr. Sun)

Shanghai First Financial News reporter also interviewed Dr. Sigman (from left: Mr. Lin, Mr. Sigman, First Financial Journalist)

Mr. Sigman took a group photo with everyone.